DUXAP10 and pachyonychia congenita: Moreover, numerous molecular mechanism experiments have confirmed that DUXAP10 plays a tumor promoter role by regulating key target gene activity and affecting multiple important signaling pathways, making it a possible molecular factor that can be used as a therapeutic target in HCC (Han et al., 2019; Sun et al., 2019), NSCLC (Wei et al., 2017), glioma (Wu et al., 2021), RCC (Chen et al., 2020), PTC (Li et al., 2020), OC (Zhang et al., 2018), GC (Xu et al., 2018), PC (Lian et al., 2018), BC (Lv et al., 2018), CRC (Lian et al., 2017) and ESCC (Wang et al., 2018).